ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Imaging Technique Identifies Consequences Of Mutation

February 24, 2012

In Brief: ASCO Letter To Clinton Urges support For Trials; Senator Praises NCI, Bristol; Berlin Back A NCI

January 15, 1993

DCT Advisors Approve $22 Mil. Set Aside For Interactive R01s Systemic Therapies

July 10, 1992

DoD Ovarian Cancer Research Program seeks proposals for FY05 funding.

October 1, 2004

DCPC Advisors OK PA On cancer Control In Disadvantaged

June 14, 1991

Hopkins to Commit Own Money for Junior Faculty Research

May 2, 1986